ACRS Archived Articles
Aclaris Therapeutics (NASDAQ:ACRS): Bolstering its Immuno-Inflammatory Pipeline Through Strategic Licensing
Published on March 11, 2025
Aclaris Therapeutics (ACRS): Pioneering Innovative Therapies for Immuno-Inflammatory Diseases
Published on November 17, 2024
Aclaris Therapeutics (ACRS): A Promising Pipeline Targeting Immuno-Inflammatory Diseases
Published on September 24, 2024